pexidartinib + durvalumab

Plexxikon MOA pexidartinib-durvalumab

Targeted Indication Status Sites link to clinicaltrials.gov

Colorectal
Pancreas Cancer

Phase 1/2a

Lyon, France
Villejuif, France
Toulouse, France

NCT02777710

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Zhu Y et al. Cancer Research. 2014; 74(18); 5057-69. Quail DF, Joyce JA. Nat Med. 2013; 19(11); 1423-37.
Mok S et al. Cancer Research. 2013; 74(1); 153-61. Qualls JE, Murray PJ. Nature Med. 2010; 16(8); 863-4.